Compare VBF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBF | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 384.3M |
| IPO Year | 1995 | 2010 |
| Metric | VBF | FENC |
|---|---|---|
| Price | $14.35 | $10.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 68.9K | ★ 243.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $182.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.42 | $5.65 |
| 52 Week High | $15.92 | $13.25 |
| Indicator | VBF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 21.50 | 40.49 |
| Support Level | N/A | $9.74 |
| Resistance Level | $15.21 | $11.28 |
| Average True Range (ATR) | 0.12 | 0.61 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 17.71 | 1.90 |
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.